Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 1:326:105-110.
doi: 10.1016/j.jad.2023.01.073. Epub 2023 Jan 30.

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

Affiliations

Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics

Otto Simonsson et al. J Affect Disord. .

Abstract

Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day as a result of such experiences. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing classic psychedelic experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.

Keywords: Adverse; CEQ; Challenging; LSD; Psilocybin; Psychedelics; Risk.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest PSH is on the scientific advisory board of Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, and Reset Pharmaceuticals Inc. OS and RC are co-founders of Eudelics AB. The remaining authors have nothing to disclose.

References

    1. Luoma JB, Chwyl C, Bathje GJ, Davis AK, & Lancelotta R (2020). A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy. Journal of Psychoactive Drugs, 52(4), 289–299. - PMC - PubMed
    1. Nutt DJ, King LA, & Phillips LD (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet, 376(9752), 1558–1565. - PubMed
    1. Rucker JJ, Marwood L, Ajantaival RLJ, Bird C, Eriksson H, Harrison J, … & Young AH. (2022). The effects of psilocybin on cognitive and emotional functions in healthy participants: results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation. Journal of Psychopharmacology, 36(1), 114–125. - PMC - PubMed
    1. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, … & Nutt DJ. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. - PubMed
    1. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, … & Griffiths RR. (2021). Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA psychiatry, 78(5), 481–489. - PMC - PubMed

Publication types